Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins

Vaccine ◽  
1991 ◽  
Vol 9 (1) ◽  
pp. 60-66 ◽  
Author(s):  
M LIFELY ◽  
S ROBERTS ◽  
W SHEPHERD ◽  
J ESDAILE ◽  
Z WANG ◽  
...  
Keyword(s):  
Membrane Proteins ◽  
Neisseria Meningitidis ◽  
Outer Membrane ◽  
Outer Membrane Proteins ◽  
Adult Males ◽  
Group B

Murine cross-reactive T-cell epitopes of Neisseria meningitidis outer membrane proteins

Vaccine ◽  
1992 ◽  
Vol 10 (3) ◽  
pp. 159-163 ◽  
Author(s):  
M.Robert Lifely ◽  
Mark V. Rogers ◽  
Jane Esdaile ◽  
Michael Payne ◽  
John P. Tite
Keyword(s):  
T Cell ◽  
Membrane Proteins ◽  
Neisseria Meningitidis ◽  
Outer Membrane ◽  
Outer Membrane Proteins ◽  
T Cell Epitopes

T-cell Recognition of Neisseria Meningitidis Outer Membrane Proteins

1991 ◽  
pp. 321-326
Author(s):  
E.J.H.J. Wiertz ◽  
J.A.M. van Gaans-van den Brink ◽  
I.G.A. Schuurman ◽  
P. Hoogerhout ◽  
J.T. Poolman
Keyword(s):  
T Cell ◽  
Membrane Proteins ◽  
Neisseria Meningitidis ◽  
Outer Membrane ◽  
Outer Membrane Proteins ◽  
Cell Recognition ◽  
T Cell Recognition

scholarly journals Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

1994 ◽  
Vol 7 (4) ◽  
pp. 559-575 ◽  
Author(s):  
J Diaz Romero ◽  
I M Outschoorn
Keyword(s):  
Membrane Proteins ◽  
Outer Membrane ◽  
Capsular Polysaccharide ◽  
Outer Membrane Proteins ◽  
Immunoglobulin A ◽  
Current Status ◽  
Short Term ◽  
Meningococcal Group ◽  
Life Threatening ◽  
Group B

Meningococcal meningitis is a severe, life-threatening infection for which no adequate vaccine exists. Current vaccines, based on the group-specific capsular polysaccharides, provide short-term protection in adults against serogroups A and C but are ineffective in infants and do not induce protection against group B strains, the predominant cause of infection in western countries, because the purified serogroup B polysaccharide fails to elicit human bactericidal antibodies. Because of the poor immunogenicity of group B capsular polysaccharide, different noncapsular antigens have been considered for inclusion in a vaccine against this serogroup: outer membrane proteins, lipooligosaccharides, iron-regulated proteins, Lip, pili, CtrA, and the immunoglobulin A proteases. Alternatively, attempts to increase the immunogenicity of the capsular polysaccharide have been made by using noncovalent complexes with outer membrane proteins, chemical modifications, and structural analogs. Here, we review the strategies employed for the development of a vaccine for Neisseria meningitidis serogroup B; the difficulties associated with the different approaches are discussed.

Sign in / Sign up

Export Citation Format

Share Document